Ann Arbor / San Francisco / Buffalo / Houston / Philadelphia / Memphis / Omaha / Washington / Durham / St. Louis / Seattle / Birmingham / Boston / Baltimore / Los Angeles / Nashville / Tampa / /
Company
Abraxis BioScience / Huntsman / AO 990 / Fox Chase / LG / Dana / AstraZeneca / /
Country
United States / /
Currency
USD / /
Event
Business Partnership / FDA Phase / /
Facility
Huntsman Cancer Institute / Memorial Sloan / University of Alabama / James Cancer Hospital / University of Utah / Roswell Park Cancer Institute / The University of Texas M / The Nebraska Medical Center / University of Michigan Comprehensive Cancer Center / Anderson Cancer Center / University School / Research Institute / Women’s Cancer Center / Solove Research Institute / Lurie Comprehensive Cancer Center of Northwestern University / Jewish Hospital / Birmingham Comprehensive Cancer Center / Kettering Cancer Center / University of Tennessee Cancer Institute / Ingram Cancer Center / UCSF Helen Diller Family Comprehensive Cancer Center / Massachusetts General Hospital Cancer Center / The Ohio State University / Fred Hutchinson Cancer Research Center / Fox Chase Cancer Center / SPARC Fort / Duke Comprehensive Cancer Center / /
IndustryTerm
treatment of breast cancer / cancer care / manufacturing / biotechnology / treatment of metastatic breast cancer / healthcare / pharmaceutical / tumor targeting technology / /
University of Michigan / University of Utah / Salt Lake City / FDA / Washington University / University of Alabama at Birmingham / University of Texas / The Ohio State University / Columbus / University of Tennessee / Northwestern University / Chicago / Stanford / /
Person
Stanford Comprehensive / H. Lee Moffitt / Lisa Schoenberg / Patrick Soon-Shiong / /
Position
Chairman and Chief Executive Officer / physician / Vice President of Specialty Care / arbiter / leader / /
Microsoft Word - NCCN AZ and Abraxis Joint Release[removed]_4_.doc